Your session is about to expire
← Back to Search
Memory-Enriched T Cells for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing the highest possible dose of memory-enriched T cells that can be given to patients with B-cell NHL that has returned after previous treatment. T cells are a type of immune cell that can recognize and kill abnormal cells of the body. Memory-enriched T cells will be made from a patient's own T cells that are genetically modified in a laboratory to make them more effective at recognizing and killing lymphoma cells. The goal of this trial is to see if this treatment can lower the chances of the cancer recurring.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have no active cancer except for my current diagnosis, or any past cancer is in complete remission.I am on medication to suppress my immune system due to an autoimmune disease.I don't have any health issues that would prevent me from undergoing a stem cell transplant.I do not have any uncontrolled illnesses, active infections, hepatitis B or C, or HIV.I have a type of aggressive B-cell lymphoma and need a stem cell transplant due to recurrence or high-risk disease.My B-cell NHL diagnosis is confirmed to be intermediate or high grade.I had a stem cell transplant without disease progression after my last treatment.I do not need medication to maintain my blood pressure and do not have heart rhythm problems.I have brain metastases from my cancer.You have had allergic reactions to drugs similar to cetuximab in the past.I am not currently on any experimental treatments or undergoing chemotherapy or radiation.I have a stored frozen T cell product ready for use.I am eligible for a stem cell transplant using my own cells.I understand the study's details and the risks and benefits of participating.I don't need extra oxygen and my oxygen level is 90% or higher without assistance.You do not have any significant problems with your brain function or new issues with movement or coordination.My kidney function is normal, with creatinine below 1.6 mg/dL.I am taking more than 5 mg/day of prednisone or its equivalent, but not including topical or inhaled steroids.You are currently participating in another research study with a different experimental treatment.I rely on corticosteroids for my health condition.I have had a stem cell transplant from a donor or myself.I am mostly able to care for myself and carry out normal activities.I do not have any ongoing infections that are not under control.
- Group 1: Arm 1 (autologous TCM-enriched T cells)
- Group 2: Arm 2 (autologous TN/MEM-enriched T cells)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA officially recognized Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells as an approved therapy?
"Due to the limited amount of research done on Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, our team at Power rated its safety as a 1. This is because this study is only in Phase 1 trials and has yet to accumulate substantial data regarding efficacy or security."
Are any slots available for patients to participate in this trial?
"As per the information provided on clinicaltrials.gov, this medical study is no longer recruiting patients. This trial was first posted in June 2014 and last updated in March 2022; however, there are still 2,690 other trials actively searching for participants presently."
Share this study with friends
Copy Link
Messenger